bemarituzumab + S-1 + oxaliplatin

Bemarituzumab is a first-in-class humanized IgG1 monoclonal antibody that selectively targets the fibroblast growth factor receptor 2b (FGFR2b), a protein overexpressed in approximately 30% of non-HER2-positive gastric and gastroesophageal junction (GEJ) cancers. Developed by Amgen following its acquisition of Five Prime Therapeutics, bemarituzumab is being evaluated in the FORTITUDE-103 trial in combination with the SOX chemotherapy regimen, which consists of the oral fluoropyrimidine S-1 (a combination of tegafur, gimeracil, and oteracil) and the platinum-based agent oxaliplatin. Bemarituzumab works by blocking the binding of FGF ligands to FGFR2b, thereby inhibiting downstream signaling pathways that drive tumor cell proliferation and survival, and it may also induce antibody-dependent cellular cytotoxicity (ADCC). The SOX regimen provides complementary cytotoxic activity through DNA cross-linking and inhibition of thymidylate synthase.

Other names

bemarituzumab + SOXbemarituzumab + S-1 + oxaliplatin